表6　ムンプスワクチン株による無菌性髄膜炎の発症率

株	国	無菌性髄膜炎の頻度
Jeryl Lynn	USA	1/1,800,000
	Germany	1/1,000,000
Urabe	Canada	1/62,000
	France(Sanofi)	1/28,400
	France(GSK)	1/120,000
	United Kingdom	1/3,800～11,000
	Japan	1/900～18,686
Leningrad-Z	Brazil	1/3,390
	Croatia	1/2,020
Hoshino	Japan	1/2,000～20,000
Torii	Japan	1/2,000～20,000

（文献10から作表）

いても，高校生や大学生の集団でムンプスの再燃が起こっている[16-19]．米国ではムンプス流行が再燃した集団では，麻疹ムンプス風疹（measles mumps rubella, MMR）ワクチンの3回目の接種を推奨している[19]．

2）その他のワクチン株

LZ株は，ロシアで開発されたLeningrad-3株を，クロアチアの研究所でニワトリ胚細胞に継代することで更に病原性を低下させた株である[10]．LZ株を用いてインド血清研究所で製造されたムンプスワクチンはアジアや中南米で使用されている．無菌性髄膜炎の発症頻度は本邦のワクチン株と同等である．東欧各国では，リスクベネフィットの観点からLZ株の無菌性髄膜炎発症率は容認できるとしてLZ株を定期接種に用いている．

Urabe AM9株は本邦の阪大微生物病研究会（微研）で開発された株で，サノフィはニワトリ胚細胞で更に継代後ワクチン株として用いている[10]．無菌性髄膜炎発症率を指標としたときの安全性はJL株よりも劣るが，有効性はJL株よりも優れている[12]．サノフィは有効性と価格面を重視し，中進国，途上国向けに輸出している．

スイスでは以前Rubini株を用いていたが，流行時の発症予防効果が低いため製造を中止した[10]．現在はイランで開発されたS-12株を線維芽細胞で更に継代したBBM-18株を用いている．

178

5．日本のムンプスワクチン株

日本ではムンプスワクチン株は5株開発されたが，現在市販されているのは星野株と鳥居株の2株だけである[11]．いずれの株もニワトリ胚細胞を用いて製造されている．

1）有効性

ムンプスが流行した保育園や学校における本邦ムンプスワクチンの有効率は79～90％である（表7）[20]．この有効率はスイスにおけるUrabe AM9株の有効率と同等であり，数字上本邦ワクチン株はJL株よりも有効性は優っている．株ごとの有効率では，K小学校での流行時の調査によると，星野株82.9％，鳥居株82.3％と両株の間には有効率に差が認められていない[21]．

三重県K市では平成20年度から公費助成によるムンプスワクチンの接種を行っており，公費助成開始後のムンプスワクチンの接種率は83％に上がっている．平成20年度以降5年間のK市の定点から報告されるムンプス患者数は，平成19年度以前9年間のムンプス報告数と比べて87％減少している[22]．接種率向上により本邦のムンプスワクチン株によるムンプス流行抑制効果が認められている．

2）ワクチン後の耳下腺腫脹

ムンプスワクチン後の耳下腺腫脹率は3％とされている[1]．三重県の調査では，ムンプスワクチン接種を受けた11,459人中，野生株が分離された例を除いた72人が，接種後30日以内に急性耳下腺腫脹を来し，耳下腺腫脹率は0.63％と以前の報告よりも低率であった（表8）[20,22]．耳下腺腫脹率を年齢群別にみると，1歳群が0.32％と一番低く，年齢が上がるにつれて上昇し，7～10歳群の腫脹率は1.31％と1歳群と比較した時のRRは4.11と高率であった．

3）ムンプスワクチン後の無菌性髄膜炎

ムンプスワクチン後の無菌性髄膜炎は，接種

20日後頃に発症するが，1週間の経過で治癒し，後遺症を遺さない予後良好な副反応である[12]．本邦では1989年からMMRワクチン接種が行われたが，ムンプスワクチンによる無菌性髄膜炎の発症率が予想よりも高かったために1993年に中止となっている[23]．ムンプスワクチンの無菌性髄膜炎発症率が，本邦ムンプスワクチン株を用いた定期接種に向けての課題となっている．

この10年間に三重県下から国立病院機構三重病院に照会されたムンプスワクチン後の髄膜炎例は5例であった（表9）[22]．発症者の年齢は3～10歳と，ムンプスワクチン接種者の年齢構成よりも高く，全員男性で，耳下腺腫脹をともない，ワクチン接種16～25日後に発症していた．

表7　ムンプスワクチンの効果（三重県）

| 場　　所 | 発症率（%） | | 有効率（%） | P 値 |
	未接種群	接種群		
保育園				
K	64.7(33/51)*	6.5(2/31)	90.0	<0.0001
S	50.8(30/59)	10.6(5/47)	79.1	<0.0001
合計	57.3(63/110)	9.0(7/78)	84.3	<0.0001
小学校				
K	46.8(73/156)	8.0(14/176)	82.9	<0.0001
星野株		8.3(11/132)	82.3	
鳥居株		8.7(2/23)	81.4	
家庭	46.9(15/32)	10.3(4/39)	78.1	0.0006

＊発症者数／対象者数　　　　　　　　　　　　　　　　　　　　　　　　（文献19,20から作表）

表8　年齢群によるムンプスワクチン後の耳下腺腫脹率（野生株分離陽性例を除く）

年齢群	接種者数	腫脹者数	腫脹率	RR	P value
1歳	7,472	24	0.32	1	ref.
2～3歳	2,436	29	1.19	3.71	<0.0001
4～6歳	1,172	14	1.19	3.72	<0.0001
7～10歳	379	5	1.31	4.11	0.00178
合計	11,459	72	0.63		

ref：reference
ムンプスワクチン後の髄膜炎例は3歳男児の1例のみ（発症率：1/11,500）
（文献21）

表9　ムンプスワクチン後の無菌性髄膜炎例（三重県）

症例	年齢（歳）	性	接種株	接種から発症までの日数（日）	耳下腺腫脹	細胞数	分離株	備考
KH	3	M	星野	19	あり	279	星野	
HO2	6	M	鳥居	25	あり	1800	鳥居	
TK	8	M	鳥居	16	あり	510	鳥居	
HO1	9	M	鳥居	25	あり	726	鳥居	
TT	10	M	星野	22	あり	N.T.	N.T.	臨床診断

N.T.：not tested　　　平均年齢：7.2±2.8歳（中央値8歳；3～10歳）
男：女＝5：0　　　　発症までの日数：21.4±3.9日（中央値22日；16～25日）

179

表7に示した年齢構成でムンプスワクチンを接種していたと仮定すると，ムンプスワクチン後の髄膜炎発症率は年齢が上がるにつれ上昇し，7〜10歳群のORは19.28である（表10）.

本邦ムンプスワクチン株による無菌性髄膜炎発症率は，2,000〜20,000接種あたり1人である[24,25]. 一方，全国のムンプス入院患者数調査から推計されるムンプスワクチン後の髄膜炎発症率は調査1では1/20,000，調査2では1/6,000である[8,9]. いずれも年齢群別の無菌性髄膜炎発症率が不明である.

本邦では平成25年度から任意接種のワクチンも，接種後に入院を要するような有害事象が生じた場合厚生労働省に届け出ることになっている. 平成25年4〜12月までの9ヶ月間にムンプスワクチンを接種し，無菌性髄膜炎の届け出があったのは11人である[26]. 9ヶ月間の出庫数から推計される無菌性髄膜炎発症率は，出庫数10万あたり1.62人と今までの報告と比べて低率である（表11）. しかも無菌性髄膜炎を発症したのは，3歳1人，8歳1人，10〜19歳5人，20歳代以上4人と，接種時の年齢が高いところに発症者は集中している.

三重県小児科医会では平成26年1月から，ムンプスワクチン後の安全性調査を行っている. 1月から3月までの3ヶ月間に接種した1,374人の年齢構成を表12に示した. 平成25年4月から12月までの9ヶ月間に出庫されたムンプスワクチンが，三重県と同じ年齢構成で接種されたと仮定すると，推定されるムンプスワクチン10万接種あたりの無菌性髄膜炎発症率は，1〜3歳群では0.185と最も低く，JL株とほぼ同等であり，10〜19歳群では13.87，20歳代以上では101.28と，年齢が高くなるにつれ上昇すると推定される.

表10 ムンプスワクチン後の髄膜炎発症リスク

年齢群	接種者数	ワクチン後の髄膜炎	OR
1歳	7,472	0	NA
2〜3歳	2,436	1	1
4〜6歳	1,172	1	2.08
7〜10歳	379	3	19.28

OR：odds ratio, NA：not applicable

表11 調査期間中の出庫数あたりの無菌性髄膜炎発症率（MHLW，副反応報告制度）

調査期間	出庫数	髄膜炎報告数	発症率（10万接種）
H25.4.1〜6.30	231,900	8	3.45
H25.7.1〜12.31	446.387	3	0.67
合計	678,287	11	1.62

無菌性髄膜炎発症率が10万接種あたり1.62であると，年間出生数120万人，接種率90%とすると，年間接種者数は108万人となり，年間のムンプスワクチン後の無菌性髄膜炎発症者数は17.5人となる.

（文献26から作表）

表12 三重県の年齢群別接種者数から算出した無菌性髄膜炎の発症リスク

	三重県	出庫数（全国）*	無菌性髄膜炎	OR	発症率（10万接種）
1〜3歳	1,093	539,569	1	1	0.185
4〜9歳	200	98,732	1	5.465	1.013
10〜19歳	73	36,037	5	74.863	13.87
20歳〜	8	3,949	4	546.5	101.28
合計	1,374	678,287	11	8.75	1.62

＊出庫数から推定される全国の接種者数

180

6.　ムンプスワクチンのリスクベネフィット

ムンプスワクチンは安全性が高い株ほど有効率が低く，有効率が高い株ほど無菌性髄膜炎を合併する頻度が高くなっている[10,12]．ムンプスワクチン株を選択するうえで問題となるのは，有効性と安全性のどちらを重視するかである．JL株と同じ安全性があり，JL株よりも免疫原性に優れた株の開発を求める意見がある[27]．

ムンプスは，発症時の年齢が高くなるほど耳下腺の腫脹率が高く，合併症である無菌性髄膜炎や難聴の発症率も，年齢が高くなるほど高頻度になる感染症である．ムンプスワクチン後の副反応の調査でも，耳下腺腫脹率や無菌性髄膜炎の発症率は，接種時の年齢が高くなるほど上昇する．ムンプスワクチンの有効性を重視し，副反応である無菌性髄膜炎の発症率をできる限り抑えるためには，有効性が高い株を無菌性髄膜炎発症率が低い低年齢で接種することが大切である．

ムンプス発症時のリスクとワクチン接種による安全性評価を表2に示した．ムンプスワクチンを定期接種化することで，無菌性髄膜炎は1/1,000以下に減少し，予後の悪い脳炎や難聴は極めてまれになる．リスクベネフィットを考えると，本邦ムンプスワクチン株は効果があるワクチンであり，2回接種でも医療経済性が認められている[28]．

現在本邦で市販されているムンプスワクチン株はJL株よりも有効性が高いと推察され，しかも1歳で接種すれば無菌性髄膜炎の発症率は低くなると推計されている．MMRワクチンによるトラウマにとらわれることなく，リスクベネフィットを考慮した科学的な判断が待たれている[29]．

7.　ま　と　め

ムンプスワクチンは，安全性を重視すると有効性が低下し，有効性を重視すると安全性が低下する．ムンプスは発症時の年齢が高くなるほど臨床症状が典型的になり，合併症の発症率が増加する感染症である．ムンプスワクチンも接種時の年齢が高くなるほど副反応である耳下腺腫脹や無菌性髄膜炎の発症率が増加する．今ま

でのデータから，本邦ムンプスワクチン株を1歳児に接種すれば，効果的にしかもJL株と同等の安全性で接種できると推察される．過去のトラウマにとらわれることなく科学的に判断することで，ムンプスワクチン定期接種化の道が開かれることを期待する．

参　考　文　献

1) Galazka AM, Robertson SE, Kraigher A ： Mumps and mumps vaccine ; a global review. Bull World Health Organ 77 : 3-14, 1999

2) 庵原俊昭，落合　仁：年齢によるムンプス臨床像の相違．小児科　43：217-222, 2002

3) 庵原俊昭：ムンプスとムンプスワクチン．日本小児科医会会報　41：95-98, 2011

4) 磯村思无：ムンプスワクチン．小児内科　10：1357-1361, 1988

5) 庵原俊昭，菅　　秀，浅田和豊，東川正宗，落合　仁，二井立恵，伊佐地真知子，渡辺正博：安全性からみた本邦ムンプスワクチンの適切な接種年齢の検討．日本小児科学会雑誌　118：1-99, 2014

6) Vuori N, Lahikainen EA, Peltonen T ： A study of 298 servicemen suffering from mumps. Acta Otolaryngol 55 : 231-236, 1962

7) Hashimoto H, Fujioka M, Kinumaki H, Kinki Ambulatory Pediatrics Study Group ： An office-based prospective study of deafness in mumps. Pediatr.Infect Dis J 28 : 173-175, 2009

8) 多屋馨子，神谷　齊，浅野喜造，堤　裕幸：水痘，流行性耳下腺炎重症化に関する全国調査．厚生労働省科学研究費補助金（新興・再興感染症研究事業）水痘，流行性耳下腺炎，肺炎球菌による肺炎等の今後の感染症対策に必要な予防接種に関する研究．平成16年度総括・分担研究年度終了報告書：40-48, 2005

9) 保坂シゲリ，小森　貴，保科　清，峯　真人，細矢光亮，五十嵐　隆：ムンプスウイルスおよび水痘・帯状疱疹ウイルス感染による重症化症例と重篤な合併症を呈した症例についての調査．日本小児科医会会報　44：182-186, 2012

10) Rubin SA, Plotkin SA ： Mumps vaccine. In Vaccine, 6th ed, Saunders, Philadelphia, pp419-446, 2013

11) 庵原俊昭：ムンプス．小児科　54：1753-1760, 2013

181

12) Bonnet M, Dutta A, Weinberger C, Plotkin SA : Mumps vaccine virus strains and aseptic meningitis. Vaccine 24 : 7037-7045, 2006

13) 木所　稔, 竹田　誠：ムンプスウイルスの新たな分類基準と国内流行状況. 病原微生物検出情報　34 : 224-225, 2013

14) 竹田　誠, 木所　稔, 庵原俊昭, 名木田章：わが国のムンプスウイルスの流行解析基盤の構築. ワクチンにより予防可能な疾患に対する予防接種の科学的根拠の確立及び対策の向上に関する研究. 平成24年度総括・分担研究報告書：48-54, 2013

15) Dayton GH, Rubin S : Mumps outbreaks in the vaccinated populations : are available mumps vaccines effective enough to prevent outbreaks? Clin Infect Dis 47 : 1458-1467, 2008

16) Dayan GH, Quinlisk MP, Parker AA, Barskey ML, Hill Schwartz JM, Hunt K, Finley CG, Leschinsky DP, O'Keefe AL, Clayton J, Kightlinger LK, Dietle EG, Berg J. Kenyon CL, Goldstein ST, Stokley SK, Redd SB, Rota PA, Rota J, Daoling B, Roush SW, Bridges CB, Santibanez TA, Parashar U, Bellini WJ, Seward JF : Recent resurgence of mumps in the United States. N Engl J Med 358 : 1580-1589, 2008

17) Greenland K, Whelan J, Fancy E, Borgert M, Hulshof K, Yap K, Swaan C, Donker T, van Binnendijk R, de Melker H, Hahne S : Mumps outbreak among vaccinated university students associated with a large party, the Netherlands, 2010. Vaccine 30 : 4676-4680, 2012

18) Barskey AE, Schulte C, Rosen JB, Handschur FF, Rausch-Phung E, Doll MK, Cummings KP, Alleyne EO, High P, Apostolou A, Blog D, Zimmerman CM, Montana B, Harpaz R, Hickman CJ, Rota PA, Rota JS, Bellini WJ, Gallagher KM : Mumps outbreak in Orthodox Jewish communities in the United States. N Engl J Med 367 : 1704-1713, 2012

19) Nelson GE, Aguon A, Valencia E, Oliva R, Guerrero ML, Reyes R, Lizama A, Diras D, Mathew A, Camacho EJ, Monforte M, Chen T, Mahamud A, Kutty PK, Hickman C, Bellini WJ, Seward JF, Gallagher K, Fiebelkorn A : Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control-Guam 2009 to 2010. Pediatr Infect Dis J 32 : 374-380, 2013

20) 庵原俊昭 : ムンプスワクチン : 現状と今後. 臨床とウイルス　38 : 386-392, 2010

21) 落合　仁, 庵原俊昭, 中野貴司, 他：小学校におけるムンプスワクチン有効性の検討. 小児科臨床　60 : 489-494, 2007

22) 庵原俊昭, 菅　　秀, 長尾みづほ, 浅田和豊, 根来麻奈美, 谷口清州, 落合　仁, 渡辺正博, 二井立恵, 伊佐地真知子：ムンプスワクチン効果に関する臨床的検討. ムンプスに関する重大なワクチンギャップを抜本的に解決するための研究. 平成25年度総括・分担研究報告書 : 17-24, 2014

23) Ueda K, Miyazaki C, Hidaka Y, Okada K, Kusuhara K, Kadoya R : Aseptic meningitis caused by measles-mumps-rubella vaccine in Japan. Lancet 346 : 701-702, 1995

24) Nagai T, Okafuji T, Miyazaki C, Ito Y, Kamada M, Kumagai T, Yuri K, Sakiyama H, Miyata A, Ihara T, Ochiai H, Shimomura K, Suzuki E, Torigoe S, Igarashi M, Kase T, Okuno Y, Nakayama T : A comparative study of the incidence of aseptic meningitis in symptomatic natural mumps patients and monovalent mumps vaccine recipients in Japan. Vaccine 25 : 2742-2747, 2007

25) Nakayama T, Onoda K : Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine 5 ; 25(3) : 570-576, 2007 Jan

26) 第9回厚生科学審議会予防接種・ワクチン分科会副反応検討部会（平成26年5月19日）資料

27) Plotkin SA : Mumps vaccine : Do we need a new one? Pediatr Infect Dis J 32 : 381-382, 2013

28) 菅原民枝, 大日康史, 多屋馨子, 及川　馨, 羽根田紀幸, 菊池　清, 加藤文栄, 山口清次, 吉川哲史, 中野貴司, 庵原俊昭, 堤　裕幸, 浅野喜造, 神谷　齊, 岡部信彦：ムンプスワクチンの定期接種化の費用対効果分析. 日本感染症学会誌　81 : 555-561, 2007

29) Plotkin SA : Is Japan deaf to mumps vaccine? Pediatr Infect Dis J 28 : 176, 2009

182

Production of inflammatory cytokines in response to diphtheria-pertussis-tetanus (DPT), *haemophilus influenzae* type b (Hib), and 7-valent pneumococcal (PCV7) vaccines

Yasuyo Kashiwagi[1,2], Akiko Miyata[3], Takuji Kumagai[4], Kouji Maehara[5], Eitarou Suzuki[6], Takao Nagai[7], Takao Ozaki[8], Naoko Nishimura[8], Kenji Okada[9], Hisashi Kawashima[2], and Tetsuo Nakayama[1]

[1]Laboratory of Viral Infection I; Kitasato Institute for Life Sciences; Tokyo, Japan; [2]Department of Pediatrics; Tokyo Medical University; Tokyo, Japan; [3]Miyata Pediatric Clinic; Tachikawa; Tokyo, Japan; [4]Kumagai Pediatric Clinic; Sapporo, Japan; [5]Maehara Pediatric Clinic; Tama, Tokyo, Japan; [6]Suzuki Pediatric Clinic; Ube, Yamaguchi Prefecture, Japan; [7]Nagai Pediatric Clinic; Takamatsu, Kagawa Prefecture, Japan; [8]Department of Pediatrics; Konan Kosei Hospital; Konan; Aichi Prefecture, Japan; [9]Department of Pediatrics; National Fukuoka Hospital; Fukuoka, Japan

Haemophilus influenzae type b (Hib) and 7-valent pneumococcal (PCV7) vaccines both became recommended in Japan in 2010. In this study, cytokine production was investigated in peripheral blood mononuclear cells (PBMCs) cultures stimulated with diphtheria and tetanus toxoids combined with acellular pertussis vaccine (DPT), Hib, and PCV7 separately or concurrent different combinations, all as final off-the-shelf vaccines without the individual vaccine components as controls. Higher IL-1β levels were produced when cultures were stimulated with PCV than with DPT or Hib, and the concurrent stimulation including PCV7 enhanced the production of IL-1β. Although Hib induced higher levels of IL-6, no significant difference was observed in IL-6 production with the concurrent stimulation. The concurrent stimulation with Hib/PCV7 and DPT/Hib/PCV7 produced higher levels of TNF-α and human G-CSF. Cytokine profiles were examined in serum samples obtained from 61 vaccine recipients with febrile reactions and 18 recipients without febrile illness within 24 h of vaccination. No significant difference was observed in cytokine levels of IL-1β, IL-4, IL-6, IL-10, IL-12, IFN-γ, MIP-1, TNF-α, and prostaglandin E2 (PGE2) in sera between the two groups. However, significantly higher levels of human G-CSF were observed in recipients with febrile illness than in those without febrile reactions. Further investigations of the significance of elevated serum G-CSF levels are required in vaccine recipients with febrile illness.

Introduction

A long-term vaccine gap occurred in Japan from 1993 when measles mumps and rubella combined vaccine (MMR) was discontinued because of the unexpectedly high incidence of aseptic meningitis caused by mumps vaccine components.[1,2] Thereafter, new vaccines were not introduced until 2008.

However, many pediatric vaccines have been approved with the implementation of recommended immunization schedules in developed countries, which shows that vaccine preventable diseases need to be controlled.[3-6] *Haemophilus influenzae* type b conjugated with tetanus toxoid (Hib) became licensed in December 2008, and 7-valent pneumococcal conjugated with recombinant diphtheria toxoid (PCV7) vaccines in February

Figure 1. IL-1β, IL-6, TNF-α, and G-CSF production in PBMCs cultures stimulated with DPT, Hib, PCV7, DPT/Hib, DPT/PCV7, Hib/PCV7, and DPT/Hib/PCV7. PBMCs were obtained from 29 individuals and culture fluids were harvested 24 h after stimulation. Cytokine concentrations were measured using BioPlex 17 cytokine panel. Each bar represents the mean concentration (•) with 95% CI.

2010, respectively. The simultaneous administration of several vaccines was recommended by the Japanese Pediatric Association, similar to the US and EU.[3,4] PCV7 had relatively more adverse reactions of fever ≥ 38 °C, swelling, tenderness at injection site, and irritability than those receiving meningococcal vaccine having the same conjugate protein.[7] Combination vaccine containing diphtheria and tetanus toxoids combined with acellular pertussis vaccine (DPT), hepatitis B, and inactivated poliovirus vaccine was generally co-administered with Hib (DPT-HBV-IPV-Hib) in the EU. The incidence of fever ≥ 38.0 °C in the concomitant administration group (DPT-HBV-IPV-Hib with PCV7) was significantly higher than that reported in the separate vaccination group, but there was no significant difference in the incidence of high fever ≥ 39.0 °C.[8,9]

All effective vaccines induce acquired immunity with the development of antigen-specific antibodies and/or cell-mediated immunity, and the stimulation of innate immunity is now considered essential. Innate immunity consists of two different patterns: pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), and controls the T and B cells to regulate acquired immune responses.[10] The stimulation of innate immunity has been found to modulate the development of an acquired immune response through the production of cytokines.[11-13] PAMPs consist of Toll-like receptors (TLRs) and retinoic acid inducible gene-based (RIG)-like receptors, which recognize the pattern of microbes.[14-16] Aluminum adjuvant

induces inflammation at the injection site, and endogenous products released from damaged cells (damage or danger associated signals) stimulate DAMP, activating inflammasomes.[17,18] These have been shown to induce the production of inflammatory cytokine IL-1β from proinflammatory molecules.[19] DPT and PCV7 contain aluminum adjuvant and stimulate NLRP3 inflammasomes through tissue damage.[19] Vaccine antigens initiate innate immune response by the recognition by PAMPs at the injection site, activating dendritic cells (DCs). Antigen is processed and peptide is presented on MHC molecules (signal 1), and antigen presenting cells are migrated to the draining lymph nodes. Type I Interferon (IFN) and inflammatory cytokines enhance the expression of co-stimulatory molecules to help the recognition by T-cell (signal 2). IFN-γ, IL-4, and IL-12 modulate the differentiation toward Th1 and Th2 responses.[18] The mechanisms of immunogenicity induced by aluminum adjuvant regarding whether the stimulation of NLRP3 inflammasomes is necessary or not have not yet been fully understood.[18-20] The activation of innate immunity by vaccines is indispensable for immunogenicity, and the enhanced production of inflammatory cytokines may be related to the occurrence of adverse events.[21] Vaccine-specific innate inflammatory responses are clearly important, and have not been sufficiently investigated regarding cytokine production using different vaccines.

In our previous report, aluminum-adjuvanted H5 whole virion inactivated vaccine (WIV) was licensed for adults in

Japan but induced marked febrile reactions with significantly stronger antibody responses in children. Aluminum adjuvant alone did not induce inflammatory cytokines, and H5 WIV induced IL-6, IL-17, TNF-α, MCP-1, IFN-γ, and IFN-α in peripheral blood mononuclear cells (PBMCs) cultures. Aluminum-adjuvanted H5 WIV enhanced IL-1β production, with similar levels of other cytokines stimulated with H5 WIV.[21] In this report, cytokine profiling was investigated using PBMCs to evaluate cytokine production in response to the stimulation of DPT, Hib, and PCV7, separately and concurrent different combinations. Since the separate components of these final vaccines were not available, only the final formulated vaccines could be used as in-vitro stimulants. Serum cytokine levels were investigated in 61 vaccine recipients with febrile reactions and 18 recipients without febrile illness within 24 h of vaccination.

Figure 2. IL-1β production in the PBMCs of 29 individuals. PBMCs were stimulated with DPT, Hib, PCV7, DPT/Hib, DPT/PCV7, Hib/PCV7, and DPT/Hib/PCV7. Columns from left to right in each individual show the production of IL-1β measured by EIA.

Results

Cytokine production in PBMCs stimulated with the single or different combinations of vaccines

Preliminary studies of cytokine production showed that cytokines began to be produced 6 h after the stimulation and increased until 24 h, showing the same level afterward, similar to the previous report of aluminum-adjuvanted H5N1 pandemic vacine.[22] Cell viability of non-stimulation was approximately 85–90%, 70–75% for non-adjuvanted vaccines, 50–60% for aluminum-adjuvanted vaccines 24 h after stimulation. PBMCs were stimulated with marketed vaccines, and culture supernatant was collected 24 h after the stimulation. Seventeen cytokine profiles were examined in PBMCs cultures obtained from 29 subjects by stimulation of single or different combinations of DPT, Hib, PCV7, DPT/Hib, DPT/PCV7, Hib/PCV7, and DPT/Hib/PCV7. IL-8, MCP-1, and MIP-1β were produced in the control culture and showed no change with the stimulation. No significant difference was observed in the levels of IL-2, IL-4, IL-5, IL-7, IL-10, IL-12, IL-13, IL-17, GM-CSF, or IFN-γ in response to the single or concurrent stimulation with different combinations of vaccines. Higher levels of IL-1β, IL-6, G-CSF, and TNF-α were produced with the concurrent stimulations than with the single stimulation, and the mean values are shown with 95% confidence intervals (CI) in **Figure 1**. DPT and Hib induced similar levels of IL-1β, 72.9 pg/ml (95% CI: 37.2–108.5 pg/ml) and 106.9 pg/ml (95% CI: 44.0–169.9 pg/ml), respectively, and 0.34 pg/ml (95% CI: 0.11–0.58 pg/ml) was detected in the control culture. PCV7 induced higher levels of IL-1β, 178.5 pg/ml (95% CI: 42.1–314.9 pg/ml). DPT/Hib and DPT/PCV7 generated similar levels of IL-1β, 212.2 pg/ml (95% CI: 124.5–299.9 pg/ml) and 289.3 pg/ml (95% CI: 158.4–429.2 pg/ml), respectively. Hib/PCV7 and DPT/Hib/PCV7 produced significantly higher levels, 433.7 pg/ml (95% CI: 226.1–641.3

pg/ml) and 510.9 (95% CI: 270.0–751.9 pg/ml), respectively. The concurrent stimulation with PCV7 induced slightly higher levels of IL-1β.

A mean of 4.56 pg/ml (95% CI: 1.3–7.8 pg/ml) of IL-6 was produced in the control cultures. The stimulation with Hib induced higher levels of IL-6 (4136.7 pg/ml, 95% CI: 1883.5–6389.9 pg/ml), while there was no significant difference in the production of IL-6 in response to the stimulation with DPT and PCV7, which showed a mean level of 2438 and 1872 pg/ml, respectively. The concurrent stimulation induced similar levels of IL-6, 3248–4033 pg/ml. No significant difference was observed in IL-6 production with the single or concurrent stimulation.

A mean of 3.53 pg/ml (95% CI: 1.85–5.21pg/ml) of TNF-α was produced in control cultures. Hib induced higher levels of TNF-α in PBMCs, 880.0 pg/ml (95% CI: 406.7–1353.4 pg/ml), than DPT (mean: 183.2 pg/ml, 95% CI: 77.0–289.3 pg/ml) or PCV7 (mean: 304.5 pg/ml, 95% CI: 51.8–557.3 pg/ml). Hib/PCV7 and DPT/Hib/PCV7 produced significantly higher levels, 1833.4 pg/ml (95% CI: 788.9–2877.9 pg/ml) and 1484.3 pg/ml (95% CI: 583.3–2385.4 pg/ml), respectively.

The results of the production of G-CSF are shown. Hib induced higher levels of G-CSF than DPT or PCV7. The concurrent stimulation with DPT/Hib, DPT/PCV7, Hib/PC V7 and DPT/Hib/PCV7 induced similar levels of G-CSF, 78.55–145.51 pg/ml.

Higher levels of IL-1β were produced in PBMC cultures stimulated with PCV7 than with DPT or Hib, and Hib induced higher levels of IL-6 and TNF-α. IL-1β levels increased in PBMCs stimulated concurrently with Hib/PCV7 and DPT/Hib/PCV7, and similar patterns of TNF-α and G-CSF production were observed in PBMC cultures. No significant difference in IL-6 production was observed when cultures were stimulated separately or concurrently.

Table 1. Number of patients with or without febrile reactions after vaccination with a different combination of vaccines

Fever +		Fever –	
DPT/Hib/PCV7	22	DPT/Hib/PCV7	4
DPT/Hib/PCV7/IPV	4	DPT/Hib/PCV7/Rota	1
DPT/Hib/PCV7/Rota	3		
DPT/Hib/PCV7/BCG	1		
PCV7/Hib	7	PCV7/Hib	6
PCV7/Hib/Rota	4	DPT/Hib	1
PCV7/DPT	1		
PCV7	9	PCV7	4
PCV7/MR	3	DPT	2
Hib	3		
PCV/Rota	1		
PCV/IPV	1		
PCV/IPV/Rota	1		
PCV/Influenza	1		
Total	61		18

DPT, Diphtheria, tetanus toxoids, combined with acellular pertussis vaccine; Hib, *Hemophilus influenzae* type b T-conjugated vaccine; PCV7, 7-valent pneumococcal conjugated vaccine; Rota, Rotavirus vaccine; BCG, Bacillus Calmette-Guérin; MR, Measles and rubella combined vaccine; IPV, Inactivated polio vaccine.

The BioPlex assay for human 17-plex shows cytokine profiles, and the actual concentrations of cytokines should be examined by quantitative EIA. IFN-α/β, IL-1β, and IL-6 were re-examined using EIA. No IFN-α/β was detected in PBMCs cultures stimulated with DPT, Hib, or PCV7, and IL-1β and IL-6 levels were similar to those obtained by the BioPlex assay. The results of IL-1β production in the 29 individuals are shown in **Figure 2**. All subjects over 5 mo old had a DPT vaccination, whereas, very few subjects had the Hib but none had PCV7 vaccination. Higher IL-1β production was noted in young infants, but decreased at around 2 y old and or older, except for two subjects (4 y and 5 mo old and 5 y and 11 mo old) who recovered from aseptic meningitis. Scale-over values of > 800 pg/ml were observed in young infants by the stimulation with multiple stimulations of Hib/PCV7 and DPT/Hib/PCV7.

Serum cytokine profiles of vaccine recipients with or without febrile illness

Experiments with PBMCs showed that inflammatory cytokines were produced in response to the vaccine preparations, but did not reflect the situation in vivo. The next concern was whether cytokines were produced in the serum after immunization. Cytokine profiles were investigated in 61 serum samples obtained from recipients who exhibited febrile illness within 24 h of being vaccinated. Eighteen serum samples were obtained from recipients without febrile illness. These samples were taken within 48 h of vaccination in both groups. The background of their vaccination is shown in **Table 1**. Based upon the data of PBMCs culture, cytokine response seemed to be different according to the number of vaccine antigens. Among 61 febrile group, 30 were immunized with three or four vaccines including DPT, Hib, and PCV7, 12 with basically two bacterial vaccines, and 19 with one to three, including one bacterial vaccine. Non-febrile group was similarly categorized. Considering the results indicating that IL-1β, IL-6, G-CSF, and TNF-α were secreted in stimulated PBMC cultures, we next investigated whether the levels of inflammatory cytokines in sera of children with febrile reaction were higher than those in sera from children that did not develop fever. The results of cytokine profiles are shown in **Figure 3**. Serum G-CSF levels were significantly higher in recipients with febrile illness than in those without febrile reactions. No detectable IL-1β was observed in sera in both febrile and non-febrile groups and no significant difference was observed in cytokine levels of IL-6 and TNF-α between the two groups. These results are summarized in **Table 2**. The mean serum levels of inflammatory cytokines IL-1β, IL-6, and TNF-α, were 0.68, 29.44, and 13.43 pg/ml in vaccine recipients with febrile reactions after the simultaneous injection of three (DPT/Hib/PCV) or four vaccines (DPT/Hib/PCV + other vaccine), and similar levels of inflammatory cytokines were produced in vaccine recipients with febrile reactions after immunization of one or two inactivated bacterial vaccines, also similar to those in non-febrile group. Cytokine profiles of ten normal subjects without vaccination were examined and the mean titers of cytokines are also shown in **Table 2**. Higher levels of IL-6, IL-10, IL-12, G-CSF, IFN-γ, and TNF-α were detected in both febrile and non-febrile groups after vaccination in comparison with those in normal subjects. No significant difference was observed in Th1 or Th2 cytokines (IL-4, IL-10, IL-12, and IFN-γ) between the two febrile and non-febrile groups. The mean G-CSF level in vaccine recipients with febrile illness was 87.24 pg/ml after three simultaneous injections, higher than those in the recipients with febrile reaction after immunization with one or two vaccines, and in the non-febrile group.

As a fever-related inflammatory protein, serum PGE2 was assayed by competitive EIA, and the results are also shown in **Table 2**. The mean serum PGE2 concentration was 148.62 pg/ml (95%CI: 90.7–206.5 pg/ml) in the febrile group immunized three vaccines, and there was no significant difference in PGE2 concentration between febrile and non-febrile groups.

Comparison of cytokine profiles of vaccine recipients with those of patients with influenza

IL-1β, IL-6, G-CSF, and TNF-α concentrations were compared with serum levels in patients with the H1N1 2009 outbreak and 18 samples from patients admitted to the hospital with acute pneumonia and 9 from outpatients (**Table 3**). Levels were higher in hospitalized patients than in outpatients, but this was not significant. IL-1β was not detected in sera obtained from outpatients and no significant difference was observed in IL-6 and TNF-α levels between the influenza outpatients and immunization groups with febrile or non-febrile illness after vaccination.

The IL-1β level was < 1pg/ml and IL-6, G-CSF and TNF-α levels were < 5pg/ml in the control group with no illness.

Discussion

Currently available vaccines are categorized into live attenuated and inactivated vaccines with or without adjuvant. They induce acquired immunity: antigen-specific cytotoxic T lymphocytes (CTL) attack infected cells and antibodies prevent infections, which are modulated by innate immunity. Innate immunity consists of two different patterns, pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs).[10] The first-line of the innate immune response depends on the TLRs expressed on dendritic cells for antigen-presenting cells, polymorph nuclear neutrophils (PMNs) and monocytes, inducing cytokines in response to the invading microorganisms.[14,23,24] They recognize viral, fungal, or bacterial components, in addition to replicative or non-replicative pathogens recognized by RIG like receptor, or warning signals by some adjuvants. Recognition by innate immune receptors activates the signaling cascades of IFN-α/β, and the nuclear factor kappa B (NF-κB)-related elevated transcription of cytokines. Cellular damage and danger signals stimulate DAMP, activating inflammasomes.[17,18] In this study, cell viability reduced to 50–60% in PBMCs stimulated with aluminum-adjuvanted vaccines, and aluminum based cellular damage may have these immunological stimulation. In our previous study, aluminum-adjuvanted H5N1 whole virion inactivated vaccine induced inflammatory cytokines, although aluminum adjuvant alone did not induce these cytokines. Inflammasomes consist of NLRP3 and apoptosis-associated speck-like protein (ASC), which is thought to be an adaptor molecule of NLRP-3, resulting in the recruitment of caspase. It induces the inflammatory cytokines, IL-1β, IL-6, and IL-18, from proinflammatory molecules.[17-20] Type I IFN enhanced the expression of co-stimulatory molecules recognized by CD8+ CTL cells, together with MHC I molecules and inflammatory cytokines for co-stimulatory molecules for MHC II, recognized by CD4+ cells. CD4+ cells differentiate to functionally different Th1 and Th2 cells to produce different subclass antibodies through cytokines. Thus, innate immunity modulates the acquired immunity induced by vaccinations, and effective vaccines theoretically have an impact on the innate immune system by acting as the agonists of TLRs, RIG-I, and NOD-like receptors, inducing the production of cytokines and chemokines.[10-13]

Innate immune systems are not fully functional at the time of birth. Human neonatal plasma showed high levels of Th2 cytokines during the first week following birth, and neonatal APCs demonstrated skewed Th2 responses.[25] Caron et al.[26] reported that the production of regulatory Th1 and Th2


Figure 3. Cytokine profiles of 61 individuals with febrile reactions within 24 h after immunization (upper panel) and those of 18 recipients without febrile illness (lower panel).

cytokines following the administration of TLR agonists was lower in cord blood than in adult blood. In contrast, TLR-stimulated pro-inflammatory cytokine (IL-1β, IL-6, and IL-8) production was markedly higher in neonates than in adults. The increased susceptibility of neonates to bacterial infections may be related to imbalanced TLR responsiveness, with enhanced pro-inflammatory cytokines and decreased regulatory cytokine production. Burl et al.[27] reported that most TLR agonists induced the production of TNF-α, IL-1β, IL-6, and IL-10 in cord blood. For most agonists, TLR-mediated TNF-α and IFN-γ responses increased from birth to one month of age and TLR8 agonists also induced the production of Th1-polarizing cytokines. In contrast, IL-1β, IL-6, and IL-10 responses to most agonists were robust at birth and remained stable through to 12 mo of age in Gambian infants relative to those in developed countries.

Studies of bacterial infections suggest that bacterial lipo-polysaccharides (LPS) act as TLR4 agonists, and vaccine antigens of the polysaccharides of Hib or PCV7 are considered to be TLR4 agonists.[28,29] DPT used in Japan is an acellular formulation with 300 μg/ml of aluminum adjuvant and PCV7 consists of 250 μg/ml of aluminum adjuvant. In this study of cytokine production by PBMCs and cytokine responses after immunization, significant differences were observed in cytokine induction, particularly for IL-1β by different vaccines and stimulation of different combinations of vaccines in PBMCs. The IL-1β levels were significantly higher in response to PCV7 than to DPT and this difference depended on the antigen-aluminum formulation.[30] IL-1β levels with the simultaneous stimulation with DPT and Hib were the same as those induced by PCV alone, but were higher with the concurrent stimulation including of PCV7. IL-1β production did not depend on the amount of aluminum adjuvant. DPT and PCV7 contain aluminum adjuvants and the concurrent stimulation with DPT and PCV7 induced higher IL-β levels, but lower than those induced by PCV7 plus Hib.

Table 2. Cytokine profiles in vaccine recipients with or without febrile reactions

	Cytokine profile in subjects with febrile reaction after immunized with			
	≥ 3 bacterial vaccines (n = 30)	2 bacterial vaccines (n = 12)	One bacterial vaccine (n = 19)	
IL-1β	0.68 (0.36～0.99)	0.78 (0.08～1.48)	0.83 (-0.02～1.67)	
IL-4	0.41 (0.26～0.56)	0.29 (0.11～0.48)	0.35 (0.14～0.57)	
IL-6	29.44 (17.35～41.53)	12.53 (6.88～18.20)	23.72 (11.53～35.90)	
IL-10	7.34 (1.97～12.71)	3.6 (0.31～6.88)	7.85 (3.04～12.66)	
IL-12	12.93 (-2.28～28.15)	6.4 (-2.61～13.07)	7.87 (1.27～14.46)	
G-CSF	87.24 (34.65～139.83)	37.41 (18.99～55.83)	39.88 (17.88～61.88)	
IFN-γ	49.95 (24.08～75.09)	42.95 (3.58～82.32)	33.26 (14.98～51.54)	
MIP-1β	66.81 (41.33～92.29)	59.97 (32.55～87.38)	72.51 (27.10～117.92)	
TNF-α	13.43 (0.25～26.62)	4.86 (1.94～7.78)	11.3 (1.49～21.11)	
PGE2*	148.62 (90.7～206.5))	114.36 (68.91～159.8)	219.3 (51.49～387.2)	
	Cytokine profile in subjects without febrile illness after immunized with			Normal (n = 10)
	≥ 3 bacterial vaccines (n = 5)	2 bacterial vaccines (n = 7)	One bacterial vaccine (n = 6)	
IL-1β	1.12 (0.04～2.21)	0.52 (0.15～0.89)	1.53 (-0.86～3.92)	0.12 (0.04～0.21)
IL-4	1.32 (-0.6～3.25)	0.22 (0.04～0.4)	0.43 (0.05-0.81)	0.21 (0.09～0.32)
IL-6	13.43 (-5.05～31.91)	21.79 (5.8～37.8)	36.60 (-233.80～97)	2.55 (0.48～4.62)
IL-10	5.96 (-8.76～20.67)	3.54 (-3.62～10.7)	7.49 (-6.66～21.65)	1.58 (-0.28～3.22)
IL-12	10.5 (-15.62～36.62)	7.1 (-4.7～18.9)	15.29 (-18.848～49.43)	0.43 (0.19～0.66)
G-CSF	7.44 (2.30～12.58)	13.32 (3.7～22.9)	5.59 (0.83～10.34)	1.18 (-0.017～2.23)
IFN-γ	61.63 (-25.64～148.89)	19.7 (-16.4～55.8)	28.18 (-29.53～85.88)	5.24 (0.66～9.82)
MIP-1β	113.06 (-116.83～342)	91.7 (52.8～130.5)	111.73 (-0.41～223.86)	48.99 (32.19～65.80)
TNF-α	4.68 (-0.03～9.38)	11.75 (-14.8～38,3)	36.36 (-6.66～79.39)	1.35 (0.11～2.59)
PGE2*	329.5 (-43.8～702.4)	170.5 (114.3～226.8)	381.13 (54.66～707.6)	Not tested

Febrile illness was observed within 24 h after immunization in 61 subjects: three bacterial vaccines with or without other vaccine (n = 30), two bacterial vaccines with or without other vaccine (n = 12), and single bacterial vaccine with or without other vaccine (n = 19). Eighteen serum samples were obtained from whom no febrile illness was observed within 24 h after immunization: three bacterial vaccines with or without other vaccine (n = 5), two bacterial vaccines with or without other vaccine (n = 7), and single bacterial vaccine with or without other vaccine (n = 6). Ten sera were obtained from normal healthy infants aged 4–15 mo of age. IL-1β, IL-4, IL-6, IL-10, IL-12, G-CSF, IFN-γ, MIP-1β, and TNF-α were assayed by Bio-Plex human 17-plex. PGE2* was assayed with the competitive EIA kit. Mean serum concentrations of cytokines are shown with 95% CI in parentheses.

Table 3. Comparison of cytokine profiles of acute phase sera obtained from admitted patients or outpatients with H1N1 pandemic 2009 influenza

Influenza	IL-1β	IL-6	G-CSF	TNF-α
Admitted	19.44	35.93	12.44	16.09
95% CI	0-54.29	19.19-52.66	7.47-17.41	3.67-28.50
Outpatients	0.8	19.5	6.26	6.55
95% CI	0-2.06	1.54-37.45	3.02-9.49	1.10-11.97

Hib induced high levels of IL-6 and no significant difference was observed in IL-6 production among the different combinations of vaccines. Hib induced higher levels of TNF-α than any other single stimulation, whereas PCV7/Hib or all three vaccines together produced higher levels than the others. In this study, there are several limitations; vaccine antigens and different backgrounds of donors' age probably related to the immunization history. PBMCs were stimulated with final vaccine products, which contain adjuvants, preservatives, and stabilizers besides vaccine antigens. The unavailability of components of each vaccine resulted in the limitation that in-vitro stimulation profiles could not be attributable to each vaccine antigen for each vaccine. These have some possibilities to influence the cytokine production in response to aluminum antigen, but the purpose of the study is to know the response to the vaccine formulations after immunization of vaccines.

PBMCs obtained from young infants produced large amounts of IL-1β, and higher levels of IL-1β, TNF-α, and G-CSF were produced when stimulated with two or three combinations of inactivated bacterial vaccines. Febrile illness developed mostly 12–16 h after vaccination and disappeared within 24–48 h. Sixty-one serum samples were obtained from febrile group and 18

from non-febrile group, and the detection of higher amounts of inflammatory cytokines was suspected. However, no significant difference was observed in cytokine profiles irrespective of febrile illness within 24 h of vaccination and no IL-1β was detected. Influenza is a common infectious disease with an abrupt onset of febrile illness and is a potent inducer of cytokines.[15,31] Compared with the acute phase of an influenza infection, cytokine profiles after vaccination were similar to those in mild-moderate outpatients infected with the 2009 pandemic strain. Higher IL-1β levels were observed in sera obtained from seriously ill patients that had been hospitalized, but no significant difference was noted. All effective vaccines induce the production of cytokines or chemokines, which modulate immunogenicity and are also involved in inducing adverse events, such as systemic febrile illness and immunotoxicity.[21,32,33] In this standpoints, IL-6, IL-10, IL-12, G-CSF, IFN-γ, and TNF-α were detected in both febrile and non-febrile groups after vaccination in comparison with those in normal subjects. Some cytokines might be associated with febrile adverse events, and others to immunogenicity, although this is not yet determined. Kamgang et al.[34] suggested IL-1β as a biomarker of vaccine immunotoxicity. When a vaccine is administered through an intramuscular or subcutaneous route, the antigen is transported from the muscle tissue to the regional lymph nodes, where immune responses occur. Since the vaccine antigen does not appear directly in blood, an experiment in which PBMCs were stimulated with vaccine antigen did not necessarily reflect the in vivo responses following vaccination. Although higher levels of cytokines were expected in the sera of patients with febrile reactions, the inflammatory cytokine profiles of febrile recipients were not different from those of recipients without febrile illness. IL-1β is known to be a strong stimulant of oxidative stress, resulting in COX-2 stimulation and prostaglandin E2 (PGE2) production. These have been clearly related to acute or chronic inflammatory conditions. Subsequent responsiveness to cytokines may be involved in febrile illness, such as PGE2 or cytokine receptors.[35,36] In this study, cytokine profiles were also investigated in patients with influenza between hospitalized and outpatients groups. However, no significant difference was observed between the groups, because extremely serious patients were not included in the hospitalized patient group. Inflammatory cytokine profiles after vaccination were similar to the outpatient group infected with the influenza virus.

It was very hard to obtain the sera especially from non-febrile group (n = 18) within 24–48 h after immunization. From the results of cytokine production by PBMCs (**Fig. 1**) when stimulated with single or different combinations, 61 subjects with febrile reactions were categorized into three subgroups: 30 were basically immunized with three vaccines DPT/Hib/PCV7, 12 with basically two bacterial vaccines (PCV7/Hib, and PCV7/DPT) and 19 with including one bacterial vaccine. Non-febrile group was similarly categorized. Therefore, the limitation of the study was too small number of the subjects to make relevant statistical comparisons. Several individuals had an additional vaccine (IPV, Rota, BCG, influenza, or MR) besides three inactivated bacterial vaccines. These additional vaccines might affect the cytokine production. But, these live viral vaccines rarely cause febrile

reaction within 24 h after vaccination. Cytokine production was examined in PBMCs culture stimulated with IPV, influenza, and MR vaccines and very low levels of inflammatory cytokines were produced (data not shown). Therefore, additional simultaneous immunization supposed to have little influence on cytokine induction in sera.

In vaccine recipients, only human G-CSF was higher in vaccine recipients with febrile reactions and was also produced in PBMCs stimulated concurrently with two or three inactivated bacterial vaccines. G-CSF acts to mobilize and recruit neutrophils to the site of inflammation from the marginal pool.[37] The initial response at the injected site was the migration of neutrophils and monocytes with increased local cytokine production of G-CSF and IL-5 in experimental mouse model.[38] Neutrophils migrated to the injection site of the aluminum-containing vaccine and caused neutrophil extracellular traps, resulting in the degranulation of neutrophil substances.[39] Aluminum adjuvants induced reactive oxygen species (ROX), which caused increased the production of prostaglandin.[40,41] But, in this study, there was no significant difference in PGE2 concentrations in sera obtained from febrile and non-febrile groups.

A recent concept in vaccine development is the vaccine immune-network because so many genes are involved in the immunogenicity of vaccines: immune effector genes, cytokine and cytokine receptor genes, and the interaction of their transcripts.[42-44] Individual immunogenicity, low responders to some vaccines, may depend on a dysfunction in the immune regulatory network and, in a reflection of immunotoxicity, racial and individual differences are suspected in clinical adverse reactions. Further investigations of the significance of elevated serum G-CSF levels are required in vaccine recipients with febrile illness.

Materials and Methods

Study design and subjects

A total of 29 healthy children without any immunological disorders were enrolled in this study of cytokine production in PBMCs cultures (n = 29; 15 males and 14 females). They were admitted to Tokyo Medical College Hospital due to minor respiratory infections or clinical tests of liver or kidney biopsy (average 34 mo of age ranged from 2 mo to 7 y and 2 mo), and blood samples were collected just before discharge after the recovery of illness. Informed consent was obtained from their parents. PBMCs were obtained by centrifugation (Ficoll-Paque™ Plus #17–5442–02, GE Healthcare Bio-science), which was subjected within three hours after taking heparinized venous blood. PBMCs were adjusted to 5×10^5 cells in 500 μl of RPMI 1640 medium supplemented with 5% FBS and adequate antibiotics in a 48-well plate. Cultures were stimulated with 50 μl of vaccine preparations and the culture supernatant was harvested 24 h later. Samples were stocked at −80 °C until Bio-Plex cytokine assay. This study protocol was reviewed and approved by the Ethics Committee of Tokyo Medical University, Tokyo, Japan.

Vaccine antigens

DPT (Kitasato), Hib (Sanofi Pasteur), and PCV7 (Pfizer) were purchased commercially. A volume of 50 μl was used for

the stimulation of a single vaccine or different combinations of DPT/Hib, DPT/PCV7, Hib/PCV7, and DTP/Hib/PCV7. DPT and PCV7 have aluminum adjuvant at the concentration of 300 ug/ml and 250 ug/ml, respectively, and Hib does not contain aluminum.

Serum samples

Serum samples were obtained from 61 vaccine recipients who had febrile illness >37.5 °C within 24–48 h after a single- or simultaneous multi-vaccine administration and the details of the immunization are shown in Table 1: DPT/Hib/PCV7 (22 cases), DPT/Hib/PCV/IPV (4 cases), DPT/Hib/PCV7/Rota (3 cases), DPT/Hib/PCV7/BCG (1 case), PCV7/Hib (7 cases), PCV7/Hib/Rota (4 cases), PCV7/DPT (1 case), PCV7 (9 cases), PCV7/MR (3 cases), Hib (3 cases), and the remaining 4 cases were of a different combination of PCV7 and others. Febrile reactions were observed mainly after immunization with PCV7 and concurrent immunization including PCV7. Serum samples were also obtained within 24–48 h from 18 recipients without febrile reactions: DPT/Hib/PCV7 (4 cases), DPT/Hib/PCV7/Rota (1 case), PCV7/Hib (6 cases), DPT/Hib (1 case), PCV7 (4 cases), DPT (2 cases). For the control subjects without vaccination, serum samples were obtained from ten normal healthy subjects aged < 1–3 y old. Serum cytokine profiles were examined by Bio-Plex and the experimental protocol was approved by the Ethics Committee of Kitasato Institute. Serum samples were collected after obtaining informed consent.

Cytokine assay

Culture supernatants and serum samples were subjected to Bio-Plex Pro™ Human Cytokine Assay 17-plex, using Bio-Plex 200 (GI17plex panel #M50-00031YV, Bio-Rad,). IFN-α, IL-1β, and IL-6 concentrations were measured using EIA kits, (Verikine human IFN-α/β serum sample ELISA kit #46100, pbl interferon source), (Quantikine human IL-1β EIA kit#DLB50, R&D Systems), and (Quantikine IL-6 EIA kit #D6050, R&D Systems), following the instruction manuals. Prostaglandin E2 was measured by competitive EIA (Prostaglandin E2 EIA Kit #KGE004B, R&D Systems).

Statistical analysis

Differences between groups were analyzed using the Mann-Whitney U-test or chi-square test, and a significant difference was defined as $P < 0.05$, using Statcel software (OMS, Saitama, Japan).

References

1. Ueda K, Miyazaki C, Hidaka Y, Okada K, Kusuhara K, Kadoya R. Aseptic meningitis caused by measles-mumps-rubella vaccine in Japan. Lancet 1995; 346:701-2; PMID:7658837; http://dx.doi.org/10.1016/S0140-6736(95)92311-X

2. Sugiura A, Yamada A. Aseptic meningitis as a complication of mumps vaccination. Pediatr Infect Dis J 1991; 10:209-13; PMID:2041668; http://dx.doi.org/10.1097/00006454-199103000-00008

3. Centers for Disease Control and Prevention (CDC). Global routine vaccination coverage, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:1520-2; PMID:22071590

4. Duclos P, Okwo-Bele JM, Gacic-Dobo M, Cherian T. Global immunization: status, progress, challenges and future. BMC Int Health Hum Rights 2009; 9(Suppl 1):S2; PMID:19828060; http://dx.doi.org/10.1186/1472-698X-9-S1-S2

5. Dennehy PH. Active immunization in the United States: developments over the past decade. Clin Microbiol Rev 2001; 14:872-908; PMID:11585789; http://dx.doi.org/10.1128/CMR.14.4.872-908.2001

6. Plotkin SA. Vaccines: the fourth century. Clin Vaccine Immunol 2009; 16:1709-19; PMID:19793898; http://dx.doi.org/10.1128/CVI.00290-09

7. Black S, Shinefield H. Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. Eur J Pediatr 2002; 161(Suppl 2):S127-31; PMID:12494258; http://dx.doi.org/10.1007/s00431-002-1064-z

8. Olivier C, Belohradsky BH, Stojanov S, Bonnet E, Petersen G, Liese JG. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants. Vaccine 2008; 26:3142-52; PMID:18502545; http://dx.doi.org/10.1016/j.vaccine.2007.11.096

9. Pichichero ME, Bernstein H, Blatter MM, Schuerman L, Cheuvart B, Holmes SJ; 085 Study Investigators. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine. J Pediatr 2007; 151:43-9, e1-2; PMID:17586189; http://dx.doi.org/10.1016/j.jpeds.2007.02.013

10. Siegrist CA. Vaccine immunology. Vaccines 6th edition, edited by Plotkin SA, Orenstein WA, Offit PA, Philadelphia, Elsevier Saunders, 2013, pp14-32.

11. Philbin VJ, Levy O. Developmental biology of the innate immune response: implications for neonatal and infant vaccine development. Pediatr Res 2009; 65:98R-105R; PMID:19918215; http://dx.doi.org/10.1203/PDR.0b013e31819f195d

12. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010; 33:464-78; PMID:21029958; http://dx.doi.org/10.1016/j.immuni.2010.10.007

13. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011; 470:543-7; PMID:21350488; http://dx.doi.org/10.1038/nature09737

14. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801; PMID:16497588; http://dx.doi.org/10.1016/j.cell.2006.02.015

15. Ichinohe T. Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design. Expert Rev Vaccines 2010; 9:1315-24; PMID:21087109; http://dx.doi.org/10.1586/erv.10.118

16. Ichinohe T, Iwasaki A, Hasegawa H. Innate sensors of influenza virus: clues to developing better intranasal vaccines. Expert Rev Vaccines 2008; 7:1435-45; PMID:18980544; http://dx.doi.org/10.1586/14760584.7.9.1435

17. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140:821-32; PMID:20303873; http://dx.doi.org/10.1016/j.cell.2010.01.040

18. Saïd-Sadier N, Ojcius DM. Alarmins, inflammasomes and immunity. Biomed J 2012; 35:437-49; PMID:23442356; http://dx.doi.org/10.4103/2319-4170.104408

19. Kool M, Soullié T, van Nimwegen M, Willart MA, Muskens F, Jung S, Hoogsteden HC, Hammad H, Lambrecht BN. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008; 205:869-82; PMID:18362170; http://dx.doi.org/10.1084/jem.20071087

20. Spreafico R, Ricciardi-Castagnoli P, Mortellaro A. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. Eur J Immunol 2010; 40:638-42; PMID:20201020; http://dx.doi.org/10.1002/eji.200940039

21. Batista-Duharte A, Lindblad EB, Oviedo-Orta E. Progress in understanding adjuvant immunotoxicity mechanisms. Toxicol Lett 2011; 203:97-105; PMID:21392560; http://dx.doi.org/10.1016/j.toxlet.2011.03.001

22. Nakayama T, Kashiwagi Y, Kawashima H, Kumagai T, Ishii KJ, Ihara T. Alum-adjuvanted H5N1 whole virion inactivated vaccine (WIV) enhanced inflammatory cytokine productions. Vaccine 2012; 30:3885-90; PMID:22507655; http://dx.doi.org/10.1016/j.vaccine.2012.04.004

23. Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 2009; 227:221-33; PMID:19120487; http://dx.doi.org/10.1111/j.1600-065X.2008.00731.x

24. Aoshi T, Koyama S, Kobiyama K, Akira S, Ishii KJ. Innate and adaptive immune responses to viral infection and vaccination. Curr Opin Virol 2011; 1:226-32; PMID:22440781; http://dx.doi.org/10.1016/j.coviro.2011.07.002

25. Saito S. Cytokine network at the feto-maternal interface. J Reprod Immunol 2000; 47:87-103; PMID:10924744; http://dx.doi.org/10.1016/S0165-0378(00)00060-7

26. Caron JE, La Pine TR, Augustine NH, Martins TB, Hill HR. Multiplex analysis of toll-like receptor-stimulated neonatal cytokine response. Neonatology 2010; 97:266-73; PMID:19955831; http://dx.doi.org/10.1159/000255165

27. Burl S, Townend J, Njie-Jobe J, Cox M, Adetifa UJ, Touray E, Philbin VJ, Mancuso C, Kampmann B, Whittle H, et al. Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. PLoS One 2011; 6:e18185; PMID:21533209; http://dx.doi.org/10.1371/journal.pone.0018185

28. Mogensen TH, Paludan SR, Kilian M, Østergaard L. Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate the inflammatory response through Toll-like receptors 2, 4, and 9 in species-specific patterns. J Leukoc Biol 2006; 80:267-77; PMID:16731773; http://dx.doi.org/10.1189/jlb.1105626

29. Latz E, Franko J, Golenbock DT, Schreiber JR. Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity. J Immunol 2004; 172:2431-8; PMID:14764714

30. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33:492-503; PMID:21029960; http://dx.doi.org/10.1016/j.immuni.2010.10.002

31. Song BM, Kang YM, Kim HS, Seo SH. Induction of inflammatory cytokines and toll-like receptors in human normal respiratory epithelial cells infected with seasonal H1N1, 2009 pandemic H1N1, seasonal H3N2, and highly pathogenic H5N1 influenza virus. Viral Immunol 2011; 24:179-87; PMID:21668359; http://dx.doi.org/10.1089/vim.2010.0125

32. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants--a balance between toxicity and adjuvanticity. Vaccine 1993; 11:293-306; PMID:8447157; http://dx.doi.org/10.1016/0264-410X(93)90190-9

33. Gribble EJ, Sivakumar PV, Ponce RA, Hughes SD. Toxicity as a result of immunostimulation by biologics. Expert Opin Drug Metab Toxicol 2007; 3:209-34; PMID:17428152; http://dx.doi.org/10.1517/17425255.3.2.209

34. Kamgang RK, Ramos I, Rodrigues Duarte L, Ghielmetti M, Freudenberg M, Dahinden C, Padovan E. Using distinct molecular signatures of human monocytes and dendritic cells to predict adjuvant activity and pyrogenicity of TLR agonists. Med Microbiol Immunol 2008; 197:369-79; PMID:18283493; http://dx.doi.org/10.1007/s00430-008-0081-6

35. Bartfai T, Conti B. Fever. ScientificWorldJournal 2010; 10:490-503; PMID:20305990; http://dx.doi.org/10.1100/tsw.2010.50

36. Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res 2004; 10:201-22; PMID:15373964

37. Furze RC, Rankin SM. Neutrophil mobilization and clearance in the bone marrow. Immunology 2008; 125:281-8; PMID:19128361; http://dx.doi.org/10.1111/j.1365-2567.2008.02950.x

38. Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O'Hagan DT, De Gregorio E, Seubert A, Wack A. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011; 29:1812-23; PMID:21215831; http://dx.doi.org/10.1016/j.vaccine.2010.12.090

39. Munks MW, McKee AS, Macleod MK, Powell RL, Degen JL, Reisdorph NA, Kappler JW, Marrack P. Aluminum adjuvants elicit fibrin-dependent extracellular traps in vivo. Blood 2010; 116:5191-9; PMID:20876456; http://dx.doi.org/10.1182/blood-2010-03-275529

40. Pang T, Wang J, Benicky J, Sánchez-Lemus E, Saavedra JM. Telmisartan directly ameliorates the neuronal inflammatory response to IL-1β partly through the JNK/c-Jun and NADPH oxidase pathways. J Neuroinflammation 2012; 9:102; http://dx.doi.org/10.1186/1742-2094-9-102; PMID:22642771

41. Kuroda E, Ishii KJ, Uematsu S, Ohata K, Coban C, Akira S, Aritake K, Urade Y, Morimoto Y. Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 2011; 34:514-26; PMID:21497116; http://dx.doi.org/10.1016/j.immuni.2011.03.019

42. Poland GA, Ovsyannikova IG, Jacobson RM. Vaccine immunogenetics: bedside to bench to population. Vaccine 2008; 26:6183-8; PMID:18598732; http://dx.doi.org/10.1016/j.vaccine.2008.06.057

43. Poland GA, Kennedy RB, Ovsyannikova IG. Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery? PLoS Pathog 2011; 7:e1002344; PMID:22241978; http://dx.doi.org/10.1371/journal.ppat.1002344

44. Buonaguro L, Pulendran B. Immunogenomics and systems biology of vaccines. Immunol Rev 2011; 239:197-208; PMID:21198673; http://dx.doi.org/10.1111/j.1600-065X.2010.00971.x

Inflammatory responses following intramuscular and subcutaneous immunization with aluminum-adjuvanted or non-adjuvanted vaccines

Yasuyo Kashiwagi[a], Mika Maeda[b], Hisashi Kawashima[a], Tetsuo Nakayama[b],*

[a] Department of Pediatrics, Tokyo Medical University, Tokyo 160-0023, Japan
[b] Kitasato Institute for Life Sciences, Laboratory of Viral Infection, Tokyo 108-8641, Japan

ARTICLE INFO

ABSTRACT

Aluminum-adjuvanted vaccines are administered through an intramuscular injection (IM) in the US and EU, however, a subcutaneous injection (SC) has been recommended in Japan because of serious muscle contracture previously reported following multiple IMs of antibiotics. Newly introduced adjuvanted vaccines, such as the human papillomavirus (HPV) vaccines, have been recommended through IM. In the present study, currently available vaccines were evaluated through IM in mice. Aluminum-adjuvanted vaccines induced inflammatory nodules at the injection site, which expanded into the intra-muscular space without any muscle degeneration or necrosis, whereas non-adjuvanted vaccines did not. These nodules consisted of polymorph nuclear neutrophils with some eosinophils within the initial 48 h, then monocytes/macrophages 1 month later. Inflammatory nodules were observed 6 months after IM, had decreased in size, and were absorbed 12 months after IM, which was earlier than that after SC. Cytokine production was examined in the injected muscular tissues and AS04 adjuvanted HPV induced higher IL-1β, IL-6, KC, MIP-1, and G-CSF levels in muscle tissues than any other vaccine, but similar serum cytokine profiles were observed to those induced by the other vaccines. Currently available vaccines did not induce muscular degeneration or fibrotic scar as observed with muscle contracture caused by multiple IMs of antibiotics in the past.

© 2014 Elsevier Ltd. All rights reserved.

1. Introduction

All vaccines have been administered through a subcutaneous injection (SC) in Japan, whereas aluminum-adjuvanted vaccines are administered through an intramuscular injection (IM) without any serious reactions in the EU, US, and many other countries [1]. IM was prohibited in Japan because serious muscle contracture was reported with multiple IMs of antibiotics with or without antipyretics in the 1960s. The first case of the muscle contracture was reported by an orthopedic surgeon in 1947, and may have been caused by IM of antibiotics. The number of these cases increased and several regional accumulations of patients were reported, especially in Yamanashi prefecture, where legal action was taken. All cases had multiple IMs of antibiotics with or without antipyretics, but not with vaccines. The Japanese Orthopedic Association announced the Precaution in 1976 that muscle contracture was mainly caused by IM of antibiotics and that pediatricians should refrain from unnecessary IM. Thereafter, an Investigational Committee on Muscle Contracture was established by the Japanese Pediatric Association, which announced the following comments in 1977 [2]:

1) Muscle contracture was reported in the quadriceps, deltoids, and buttocks, and no site was safe for IM.
2) Muscle contracture was reported in all age groups, not just in young infants.
3) The indication of IM was extremely rare.
4) Informed consent had to be obtained from patients or their guardian in cases in which IM was required.

The histopathological findings obtained from the muscle tissues of the patients revealed the infiltration of inflammatory cells, degeneration of muscle cells, necrosis, fibrosis, and scar formation, which were similar to those observed in experimental animals following IM of various antibiotics [3–5]. IM was

* Corresponding author at: Shirokane 5-9-1, Minato-ku, Tokyo 108-8641, Japan.
Tel.: +81 3 5791 6269; fax: +81 3 5791 6130.
E-mail address: tetsuo-n@lisci.kitasato-u.ac.jp (T. Nakayama).

subsequently prohibited for all medicinal procedures except the administration of immunoglobulin preparations. All vaccines were administered through SC, and the Committee on Muscle Contracture also suggested that all medicinal preparations for IM had to be histopathologically examined in the muscle tissues of experimental animals to assess the damage to muscle tissue [2].

Serious local reactions were previously reported following immunization with diphtheria and tetanus toxoids combined with the acellular pertussis vaccine (DPT) containing an aluminum adjuvant, and the precise mechanisms underlying local reactogenicity and immunogenicity have not fully elucidated [6–8]. In addition to a conventional aluminum adjuvant, a new vaccine containing monophosphoryl lipid A (MPL) was introduced [9]. Aluminum has been used as an adjuvant for a long time because it prolongs the retention of adsorbed antigens at the injection site (depot effect), however, recent findings on innate immunity have indicated that aluminum adjuvants initiate primary immune-stimulation in the innate immune system [10,11]. Innate immunity consists of two different patterns: pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). All effective vaccines stimulate the innate immune system to produce cytokines or chemokines for the development of acquired immune responses through the expression of co-stimulatory molecules [12–14]. These reactions start in the early phase following the injection: therefore an investigation of local reactions following a vaccination appears to be warranted to better understand the safety and immunogenicity of vaccines [12,15,16].

Haemophilus influenzae type b (Hib) was introduced in Japan in 2008, 7-valent pneumococcal (PCV7) and human papillomavirus (HPV) vaccines in 2010 [17]. These newly introduced vaccines are administered through IM in other countries. However, only HPV vaccines are recommended through IM, as is stated on the package inserts. Vaccination against HPV has been associated with a chronic pain syndrome in Japan, although a causal relationship has not been established [18]. All routine vaccines, including newly introduced ones, have not been examined to assess the safety of IM administration: therefore, histopathological findings and local cytokine production were investigated in the present study using current available inactivated vaccines.

2. Materials and methods

2.1. Vaccines

All routine inactivated vaccines were examined. DPT (Kitasato Institute, Japan), Hib (Sanofi Pasteur, France), PCV7 (Pfizer, USA), the Japanese Encephalitis vaccine (JEV) (Biken, Japan), seasonal influenza split vaccine (Kitasato Institute, Japan), 4-valent HPV (Gardasil: MSD, USA), and 2-valent HPV (Cervarix: GSK, Belgium) were purchased commercially.

2.2. Experimental design

Four-week-old BALB/c mice were purchased from Charles River, US. All vaccines were administered in 100 μl volume through IM in the left quadriceps muscle in four mice for each vaccine (1/5 volume of human dose) and phosphate-buffered saline (PBS) at the right quadriceps muscle for the control. Muscle tissues were examined 1 month after a single injection to compare histological findings by different vaccine preparations. Mice were immunized with three doses of DPT through IM in the same left quadriceps, or through SC in the back of the neck, to compare pathological findings through IM and SC. Injection sites were examined 1, 3, 6, 9, and 12 months after the injection to assess local reactions. Sera were also obtained to compare serological responses.

To assess cytokine responses and histological findings at very early phase following the injection, quadriceps muscle tissues and serum samples were obtained pre, 3, 6, 24, and 48 h after a single injection of DPT, Hib, PCV7, JEV, Cervarix, and Gardasil in three mice for each point. PBS was injected in the opposite quadriceps as the control.

2.3. Histological examinations

Quadriceps muscle tissues were fixed with 10% phosphate-buffered formalin and decalcified in PBS before embedding in paraffin. Muscle and subcutaneous tissues were stained with hematoxylin and eosin (HE) using a conventional procedure. Lumogallion staining was performed and aluminum compounds were visualized through confocal microscopy [19]. Macrophages were stained with antibodies against F4/80 (a rat monoclonal antibody against mouse F4/80, AbD Serotec, USA), iNOS (polyclonal rabbit anti-iNOS/NOS type II, BD, USA), and arginase I (rabbit polyclonal antibody against human arginase, Santa Cruz, USA) [20–22].

2.4. Cytokine productions

Quadriceps muscles were harvested, cut into small pieces, and homogenized with 2 ml of RPMI supplemented with 1% protease inhibitor (nacalai tesque, Kyoto, Japan) using Bio Masher II (Nippi, Tokyo, Japan). The muscle homogenate was centrifuged, filtrated through a 0.45 μm filter, and subjected to a cytokine assay. IL-1β, IL-2, IL-4, IL-6, IL-10, Eotaxin, G-CSF, KC, MCP-1, and TNF-α were measured using the BioPlex mouse cytokine panel (BioPlex, Bio-Rad Laboratories, USA). The local production of cytokines was expressed as the ratio of the cytokine concentration at the injected site to that at the opposite site injected with PBS, and the mean of three mice was shown for each cytokine.

2.5. Statistical analyses

Differences between the groups were analyzed using Cochran–Cox method and a significant difference was defined as $p < 0.05$, using StatMate software (ATMS, Tokyo).

3. Results

3.1. Histological findings 1 month after the single dose injection

Hib, influenza, and JEV do not contain aluminum adjuvant. The DPT vaccine consists of 300 μg/ml of aluminum, PCV 250 μg/ml, Gardasil 450 μg/ml, and Cervarix contains 1.0 mg/ml together with 100 μg/ml of monophosphoryl lipid A (MPL) adjuvant. Histological findings following IM immunization are shown in Fig. 1. Histopathological findings differed in muscle tissues injected with aluminum-adjuvanted or non-adjuvanted vaccines. No significant difference was observed in the pathological findings obtained from tissues injected with non-adjuvanted JEV vaccine. However, one of the three mice injected with Hib exhibited small localized focal inflammatory reactions with the infiltration of inflammatory and myogenic cells. Similar findings were observed in one of the four mice immunized with the influenza vaccine. Non-adjuvanted vaccines induced no significant pathological differences or small localized inflammatory reactions.

Aluminum-adjuvanted vaccines induced inflammatory nodules with the infiltration of inflammatory cells or macrophages at the marginal lesions. Inflammatory nodules spread into muscle bundle spaces without the degeneration of or atrophic changes to muscle cells. Infiltrating cells were characterized as macrophages: ballooned cytoplasm with peripherally localized nucleus. Lumogallion staining was performed to visualize the aluminum adjuvant

Fig. 1. Histological findings of HE staining 1 month after the inoculation with aluminum - adjuvanted and non-adjuvanted vaccines. DPT, PCV7, HPV Gardasil, and HPV Cervarix were used as aluminum-adjuvanted vaccines (Alum+). Hib, JEV, and seasonal influenza split vaccines were used as non-adjuvanted vaccines (Alum−). Three or four mice were inoculated through IM and the quadriceps muscles were removed 1 month after the injection.

and the results are shown in Fig. 2. No aluminum positive cells were observed in muscle tissues injected with Hib, or in the control. Weak staining was observed in the inflammatory nodules in muscle tissues injected with DPT, PCV7, and Gardasil. Aluminum was homologously visualized in the inflammatory nodules of muscle tissue injected with Cervarix. Aluminum was engulfed in the cytoplasm of ballooned macrophages, resulting in macrophagic nodules.

Fig. 2. Aluminum staining 1 month after the inoculation of vaccines. The results of Lumogallion staining are shown 1 month after the inoculation with DPT, PCV7, HPV Gardasil, and HPV Cervarix. Regarding the control, the results of phosphate-buffered saline (PBS) and Hib (non-aluminum) are shown.

Fig. 3. Characteristics of inflammatory cells in the inflammatory nodules, inflammatory nodules were observed after the inoculation with aluminum-adjuvanted vaccines. The results of HE staining and immuno-staining with F4/80, iNOS, and arginase I are shown after the inoculation with DPT, HPV Gardasil, and HPV Cervarix.

Histological findings following IM of Cervarix, which contains MPL, appeared to be different from those in muscle tissues injected with DPT, PCV7, and Gardasil, in which aluminum is used as an adjuvant at different concentrations. Macrophages were stained with F4/80, iNOS, and arginase I, and the results are shown in Fig. 3. The inflammatory nodules were investigated 1 month after IM. Migrated cells located at the marginal lesions of inflammatory nodules in muscle tissue injected with DPT and Gardasil were stained with F4/80, iNOS, and arginase I. However, those infiltrated after IM of Cervarix were positive for F4/80 and weakly positive for arginase I, but not for iNOS.

3.2. Comparison of histological findings through SC and IM

No histopathological differences were observed following IM of non-adjuvanted vaccines. Aluminum-adjuvanted vaccines induced similar histological changes, except for Cervarix. The DPT vaccine is a basic vaccine for young infants and is administered through SC, which is recommended by the immunization law in Japan. Histological changes were compared 1, 3, 6, 9, and 12 months after IM or SC of three doses with a four-week interval in three mice for each group. Histological changes 1 month after the three injections were similar to those 1 month after the single dose, as shown in Fig. 1, and those observed 3, 6, and 9 months after immunization are shown in Fig. 4. Inflammatory nodules were relatively larger 3 months after IM than those after SC, but became smaller 6 months after IM. Histological findings of nodules after IM were similar to those after SC, and their sizes were the same until 9 months after the injection.

Histopathological changes were compared 1 year after SC and IM of three doses of DPT and the results are shown in Fig. 5. Three mice were examined: inflammatory nodules remained in two mice after SC but not in one mouse. Although IM initially induced large inflammatory nodules, this appeared to be absorbed earlier than SC, and inflammatory nodule remained in one among three mice through IM administration.

3.3. Production of cytokines at the injection site and serum cytokine profiles

All effective vaccines have stimulatory signals that activate the innate immune response to induce acquired immunity through the production of cytokines or chemokines. These vaccines are associated with the occurrence of the local reactions, indurations, swelling, redness, and erythema, and/or occasionally with the systemic adverse events such as fever. Cytokine production was investigated in the early phase following immunization with DPT, Hib, PCV7, JEV, and two HPV vaccines (Cerverix and Gardasil). The quadriceps muscles were dissected from both injected and non-injected sites, and were homogenized. IL-1β, IL-2, IL-4, IL-6, IL-10, Eotaxin, G-CSF, KC, MCP-1, and TNF-α were assayed. Cytokine production was expressed as the ratio of the cytokine concentration in the injected site to that in the non-injected site, and the results of local production are shown in Fig. 6. Changes in TNF-α levels are shown, and ranged between 0.5 and 1.5 fold of those in the injected sites. No significant difference was observed in the cytokine ratios of the injected and non-injected sites for IL-2, IL-4, IL-10, and Eotaxin, which was similar to that of TNF-α. IL-1β levels were 9.8 times higher (injected site 254.26: control 30.57 pg/ml) after 3 h and increased to 47.7 times (injected site1049.46: control 28.33 pg/ml) 48 h after the inoculation with Cervarix. IL-1β levels were from 2.33 to 2.80 times higher (41.45–84.78 pg/ml) following the inoculation of Gardasil, but were approximately 2-3 times or lower following inoculation with the other vaccines. G-CSF levels were 276 times higher (injected site 96.71: control 0.58 pg/ml) 48 h after the inoculation with Cervarix, and were 23 times higher (injected site 8.78: control 0.59 pg/ml) 24 h after the inoculation with Gardasil. These levels were 13.26 times higher 6 h after DPT and 5.73 times higher 3 h after Hib. IL-6 levels were 139 times higher (injected site 127.26: control 1.09 pg/ml) 48 h after the injection with Cervarix, while the other vaccines increased IL-6 levels by 2-3 times (1.55–4.14 pg/ml). Cervarix induced higher levels of IL-1β, IL-6, and G-CSF, but not significant. It also induced higher MIP-1 levels at 3 h, and these were decreased at 6 h. Higher

## Subcutaneous inoculation   Intramuscular inoculation

Fig. 4. Comparison of histological changes after the immunization with three doses of DPT. Injected tissues were obtained 3, 6, and 9 months after the immunization with three doses, and were examined with HE and Lumogallion staining.

levels of these cytokines were induced at 24 and 48 h, and Gardasil induced a similar MIP-1 production pattern (data not shown).

The results of serum cytokine kinetics are shown in Fig. 7. Five mice were assayed and the mean concentrations of five sera are shown. Peaks of IL-1β levels were detected 6 h after the injection of all vaccines, except Hib, which induced peak IL-1β levels 24 h after the injection. Higher IL-1β levels were detected after the injections with PCV7, JEV, and Cervarix. Hib induced a peak in serum G-CSF

levels 3 h after the injection, DPT and Cervarix at 6 h, and PCV7 at 24 h. A significant higher level of IL-6 was observed 3 h after the injection with Cervarix, in comparison with those after the other vaccines, but decreased to the similar level 6 h after the injection with PCV7. All vaccines induced TNF-α and their peak levels were observed within 24 h of the injection with no significant difference.

Cervarix induced extremely high IL-1β, IL-6, and G-CSF levels at the injection site, but, however, systemic serum cytokine levels were similar to the others.

DPT SC 1 year after three doses   DPT IM 1 year after three doses

Fig. 5. Comparison of histological changes one year after the immunization with three doses of DPT. Injected tissues were examined with HE and Lumogallion staining.

6   *Y. Kashiwagi et al. / Vaccine xxx (2014) xxx–xxx*

Fig. 6. Cytokine production in muscle tissues injected with DPT, Hib, PCV, JEV, Cervarix, and Gardacil. The quadriceps muscles were removed, homogenized, and subjected to BioPlex cytokine panels 3, 6, 24, and 48 h after the injection. Cytokine production was shown as the ratio of the cytokine concentration in the injected site to that in the opposite site. Each bar represents the mean ratio with ±1.0 SD of three mice.

3.4. Histopathological findings in the early phase following the injection

Cervarix induced higher levels of cytokines at the injection site than those by the other vaccines. Histopathological findings were examined after IM of Cervarix, Gardasil, and JEV. JEV induced no inflammatory responses 1 month after IM, as is shown in Fig. 1, and no pathological changes in the very early phase (data not shown). HE and Lumogallion staining of the series of IM of Cervarix are shown in Fig. 8. Inflammatory nodules were observed 3 h after IM and the predominant infiltrating cells were polymorph nuclear neutrophils (PMNCs) with some eosinophils. Migrating cells engulfing aluminum were observed in the draining inguinal

lymph node 48 h after the injection. These results were similar to those observed after the injection with Gardacil.

4. Discussion

The number of reported cases of muscle contracture increased in the 1960s. The histopathological findings of muscle contracture revealed the infiltration of inflammatory cells, muscle cellular necrosis, fibrosis, and scar tissue formation, similar to that in an experimental animal model, and the Investigation Committee on Muscle Contracture suggested that the histopathological changes induced in the muscle tissues of experimental animals by all medicinal preparations through IM should be


Fig. 7. Kinetics of serum cytokine production after the injection with DPT, Hib, PCV, JEV, Cervarix, and Gardacil. Serum samples were obtained 3, 6, 24, and 48 h after the injection. Each bar represents the mean ratio with ±1.0 SD of there mice.

Please cite this article in press as: Kashiwagi Y, et al. Inflammatory responses following intramuscular and subcutaneous immunization with aluminum-adjuvanted or non-adjuvanted vaccines. Vaccine (2014), http://dx.doi.org/10.1016/j.vaccine.2014.04.018